$59.58
0.52% yesterday
Nasdaq, Oct 15, 10:00 pm CET

Bio-Techne Corporation Stock price

$59.58
+7.96 15.42% 1M
+8.51 16.66% 6M
-12.45 17.28% YTD
-14.01 19.04% 1Y
-14.46 19.53% 3Y
-6.81 10.26% 5Y
+36.13 154.07% 10Y
+45.74 330.34% 20Y
Nasdaq, Closing price Wed, Oct 15 2025
+0.31 0.52%

Key metrics

Basic
Market capitalization
$9.3b
Enterprise Value
$9.5b
Net debt
$183.8m
Cash
$162.2m
Shares outstanding
155.0m
Valuation (TTM | estimate)
P/E
132.4 | 29.0
P/S
7.6 | 7.3
EV/Sales
7.8 | 7.5
EV/FCF
36.9
P/B
4.8
Dividends
DPS
$0.32
Yield 1Y | 5Y
0.5% | 0.4%
Growth 1Y | 5Y
0.0% | 0.0%
Payout 1Y | 3Y
69.6% | 29.4%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$1.2b | $1.3b
EBITDA
$375.0m | $450.6m
EBIT
$265.0m | $411.1m
Net Income
$72.3m | $318.8m
Free Cash Flow
$256.6m
Growth (TTM | estimate)
Revenue
-15.1% | 4.0%
EBITDA
-9.8% | 51.9%
EBIT
-12.8% | 54.9%
Net Income
-67.0% | 334.5%
Free Cash Flow
8.7%
Margin (TTM | estimate)
Gross
66.5%
EBITDA
30.7% | 35.5%
EBIT
21.7%
Net
5.9% | 25.1%
Free Cash Flow
21.0%
Financial Health
Equity Ratio
75.0%
Return on Equity
3.8%
ROCE
11.1%
ROIC
8.5%
Debt/Equity
0.2
More
EPS
$0.5
FCF per Share
$1.7
Short interest
4.0%
Employees
3k
Rev per Employee
$390.0k
Show more

Is Bio-Techne Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Bio-Techne Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Bio-Techne Corporation forecast:

18x Buy
78%
5x Hold
22%

Analyst Opinions

23 Analysts have issued a Bio-Techne Corporation forecast:

Buy
78%
Hold
22%

Financial data from Bio-Techne Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1,220 1,220
15% 15%
100%
- Direct Costs 409 409
15% 15%
34%
811 811
15% 15%
66%
- Selling and Administrative Expenses 446 446
16% 16%
37%
- Research and Development Expense 100 100
18% 18%
8%
375 375
10% 10%
31%
- Depreciation and Amortization 110 110
2% 2%
9%
EBIT (Operating Income) EBIT 265 265
13% 13%
22%
Net Profit 72 72
67% 67%
6%

In millions USD.

Don't miss a Thing! We will send you all news about Bio-Techne Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bio-Techne Corporation Stock News

Neutral
Business Wire
about 21 hours ago
QUEBEC CITY--(BUSINESS WIRE)-- #cellpainting--Saguaro Biosciences, a pioneer in non-toxic live cell reagents for enhanced drug insights, announces a new distribution agreement with Bio-Techne Corporation (NASDAQ:TECH), a global provider of life science tools, reagents and diagnostic products. The partnership will leverage Bio-Techne's extensive international sales and marketing channels to prov...
Neutral
PRNewsWire
about 23 hours ago
MINNEAPOLIS , Oct. 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, November 5, 2025, at 8:00 a.m. CST to review its first quarter fiscal 2026 financial results.
Neutral
PRNewsWire
7 days ago
Grants Bio-Techne expanded commercial rights to develop a portfolio of genetics products beyond the recently launched AmplideX® Nanopore Carrier Plus Kit Establishes a framework to define and propose future portfolios Extends collaboration through 2032, reinforcing Bio-Techne's diagnostics growth strategy and strengthening relationship with Oxford Nanopore Technologies MINNEAPOLIS , Oct. 9, 202...
More Bio-Techne Corporation News

Company Profile

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Biotechnology, Protein Platforms, Diagnostics, and Corporate. The Biotechnology segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and related reagents, as well as in situ hybridization, media and other cell culture products and reagents to the biotechnology research community. The Protein Platforms segment develops, manufactures, and sells tools to simplify protein analysis. The Diagnostics segment includes blood chemistry and blood gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market worldwide. The company was founded on 1976 and is headquartered in Minneapolis, MN.

Head office United States
CEO Kim Kelderman
Employees 3,100
Founded 1976
Website www.bio-techne.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today